Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2019

01-09-2019 | Esophageal Cancer | Thoracic Oncology

Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy

Authors: Wei Deng, MD, Wencheng Zhang, MD, Jinsong Yang, MD, Wenjie Ni, MD, Shufei Yu, MD, Chen Li, MD, Xiao Chang, MD, Zongmei Zhou, MD, Dongfu Chen, MD, Qinfu Feng, MD, Xiaohui Chen, MD, Yu Lin, MD, Kunshou Zhu, MD, Xiongwei Zheng, MD, Jie He, MD, Shugeng Gao, MD, Qi Xue, MD, Yousheng Mao, MD, Guiyu Cheng, MD, Kelin Sun, MD, Xiangyang Liu, MD, Dekang Fang, MD, Junqiang Chen, MD, Zefen Xiao, MD

Published in: Annals of Surgical Oncology | Issue 9/2019

Login to get access

Abstract

Background

Effective tools evaluating the prognosis for patients with esophageal cancer undergoing surgery is lacking. The current study aimed to develop a nomogram to predict overall survival (OS) and provide evidence for adjuvant therapy for patients with esophageal carcinoma after esophagectomy.

Methods

The study retrospectively reviewed patients with pathologic T1N +/T2-4aN0-3, M0 thoracic esophageal squamous cell carcinoma after radical esophagectomy, with or without adjuvant therapy, in one institution as the training cohort (n = 2281). A nomogram was established using Cox proportional hazard regression to identify prognostic factors for OS, which were validated in an independent validation cohort (n = 1437). Area under curve (AUC) values of receiver operating characteristic curves were calculated to evaluate prognostic efficacy.

Results

In the training cohort, the median OS was 50.46 months, and the 5-year OS rate was 47.08%. Adjuvant therapy, sex, tumor location, grade, lymphovascular invasion, removed lymph nodes, and T and N categories were identified as predictive factors for OS. The nomogram showed favorable prognostic efficacy in the training and validation cohorts (5-year OS AUC: 0.685 and 0.744, respectively), which was significantly higher than that of the American Joint Committee on Cancer (AJCC) staging system. The nomogram distinguished OS rates among six risk groups, whereas AJCC could not separate the OS of 2A and 1B, 3C and 3B, or 3A and 2B. Patients with a nomogram score of 72 to 227 were predicted to achieve a 5-year OS increase of 10% or more from adjuvant therapy.

Conclusion

The nomogram could effectively predict OS and aided decision making in adjuvant therapy for patients with thoracic esophageal squamous cell carcinoma after esophagectomy.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.CrossRefPubMed
3.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
4.
Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRef
5.
Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23:1095–103.CrossRefPubMed
6.
Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, et al. American Joint Committee on Cancer Staging System does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507–12.CrossRefPubMed
7.
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRefPubMed
8.
Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33:861–9.CrossRefPubMed
9.
Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122:3307–15.
10.
Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–33.CrossRefPubMed
11.
Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616–23.CrossRefPubMed
12.
Liu Q, Cai XW, Wu B, Zhu ZF, Chen HQ, Fu XL. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy. PloS One. 2014;9:e97225.CrossRefPubMedPubMedCentral
13.
Hsu PK, Wang BY, Huang CS, Wu YC, Hsu WH. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg. 2011;15:558–65.CrossRefPubMed
14.
Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol. 2010;5:707–12.CrossRefPubMed
15.
Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.CrossRefPubMed
16.
Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979–85.CrossRefPubMed
17.
Schreiber D, Rineer J, Vongtama D, Wortham A, Han P, Schwartz D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5:244–50.CrossRefPubMed
18.
Worni M, Martin J, Gloor B, Pietrobon R, D’Amico TA, Akushevich I, et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg. 2012;215:643–51.CrossRefPubMedPubMedCentral
19.
Wong AT, Shao M, Rineer J, Lee A, Schwartz D, Schreiber D. The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma. Ann Surg. 2017;265(6):1146–51.CrossRefPubMed
20.
Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003;75:331–6.CrossRefPubMed
21.
Yang J, Zhang W, Xiao Z, Wang Q, Zhou Z, Zhang H, et al. The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T3N0M0 esophageal carcinoma: a propensity score-matched analysis. J Thorac Oncol. 2017;12:1143–51.CrossRefPubMed
22.
Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.CrossRefPubMed
23.
Zhang SS, Yang H, Xie X, Luo KJ, Wen J, Bella AE, et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies. Dis Esophagus. 2014;27:574–84.CrossRefPubMed
24.
Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K, et al. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node-positive thoracic esophageal squamous cell carcinoma? J Surg Oncol. 2014;110:864–8.CrossRefPubMed
25.
Eil R, Diggs BS, Wang SJ, Dolan JP, Hunter JG, Thomas CR. Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis. Cancer. 2014;120:492–8.CrossRefPubMed
26.
Zheng Y, Fu S, He T, Yan Q, Di W, Wang J. Predicting prognosis in resected esophageal squamous cell carcinoma using a clinical nomogram and recursive partitioning analysis. Eur J Surg Oncol. 2018;44(8):1199–204.CrossRefPubMed
27.
Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012;30:2265–72.CrossRefPubMedPubMedCentral
28.
Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763–73.
29.
Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1–8.CrossRefPubMed
30.
Dickson GH, Singh KK, Escofet X, Kelley K. Validation of a modified GTNM classification in peri-junctional oesophago-gastric carcinoma and its use as a prognostic indicator. Eur J Surg Oncol. 2001;27:641–4.CrossRefPubMed
31.
Khan OA, Alexiou C, Soomro I, Duffy JP, Morgan WE, Beggs FD. Pathological determinants of survival in node-negative oesophageal cancer. Br J Surg. 2004;91:1586–91.CrossRefPubMed
32.
Dikken JL, Coit DG, Klimstra DS, Rizk NP, van Grieken N, Ilson D, et al. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision. Cancer. 2012;118:349–57.
33.
Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118:3670–80.CrossRefPubMed
34.
Lee JH, Jang HS, Kim JG, Cho HM, Shim BY, Oh ST, et al. Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision. Ann Surg Oncol. 2012;19:1213–21.CrossRefPubMed
35.
Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113:1427–33.CrossRefPubMedPubMedCentral
36.
Chen WH, Huang YL, Chao YK, Yeh CJ, Chang HK, Tseng CK, et al. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2015;22:338–43.CrossRefPubMed
37.
Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153:526–34.CrossRefPubMed
38.
Huang Q, Luo K, Chen C, Wang G, Jin J, Kong M, et al. Identification and validation of lymphovascular invasion as a prognostic and staging factor in node-negative esophageal squamous cell carcinoma. J Thorac Oncol. 2016;11:583–92.CrossRefPubMed
39.
Groth SS, Virnig BA, Whitson BA, DeFor TE, Li ZZ, Tuttle TM, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg. 2010;139:612–20.CrossRefPubMed
40.
Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46–50.CrossRefPubMed
41.
Su D, Zhou X, Chen Q, Jiang Y, Yang X, Zheng W, et al. Prognostic nomogram for thoracic esophageal squamous cell carcinoma after radical esophagectomy. PloS One. 2015;10:e0124437.CrossRefPubMedPubMedCentral
42.
Zheng Y, Fu S, He T, Yan Q, Di W, Wang J. Predicting prognosis in resected esophageal squamous cell carcinoma using a clinical nomogram and recursive partitioning analysis. Eur J Surg Oncol. 2018;44:1199–204.CrossRefPubMed
Metadata
Title
Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy
Authors
Wei Deng, MD
Wencheng Zhang, MD
Jinsong Yang, MD
Wenjie Ni, MD
Shufei Yu, MD
Chen Li, MD
Xiao Chang, MD
Zongmei Zhou, MD
Dongfu Chen, MD
Qinfu Feng, MD
Xiaohui Chen, MD
Yu Lin, MD
Kunshou Zhu, MD
Xiongwei Zheng, MD
Jie He, MD
Shugeng Gao, MD
Qi Xue, MD
Yousheng Mao, MD
Guiyu Cheng, MD
Kelin Sun, MD
Xiangyang Liu, MD
Dekang Fang, MD
Junqiang Chen, MD
Zefen Xiao, MD
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07393-w

Other articles of this Issue 9/2019

Annals of Surgical Oncology 9/2019 Go to the issue

Breast Oncology

Clinical Validation of the BREAST-Q Breast-Conserving Therapy Module

Health Services Research and Global Oncology

Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility

Pancreatic Tumors

Quality of Life Following Major Laparoscopic or Open Pancreatic Resection

ASO Author Reflections

ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma?

Colorectal Cancer

Assessment of the Value of Comorbidity Indices for Risk Adjustment in Colorectal Surgery Patients

Colorectal Cancer

Bridging the Gap: Making Sense of the Diverging Evidence for Self-Expandable Metallic Stents in Malignant Colonic Obstructions